John Chawluk, MD
Neurology · Pottsville, PANPI 1376548594
Payments from drug & device makers
Across 657 payments — averaging $403.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$68K
- Teva Pharmaceuticals USA, Inc.$65K
- Biohaven Pharmaceuticals, Inc.$61K
- Biohaven Pharmaceutical Holding Company Ltd.$45K
- EMD Serono, Inc.$18K
- Abbott$3K
- plus $6K from 48 others
What the payments were for
- Consulting fees$2,9501%
- Speaking & faculty fees$204,46377%
- Travel & lodging$42,28116%
- Food & beverage$15,2836%
- Education$1710%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$104,280
- AJOVY$63,815
- UBRELVY$49,281
- QULIPTA$27,535
- INFINITY$1,569
- VNS Therapy$940
- PROCLAIM$535
- Mavenclad$358
- Infinity DBS Pulse Generators$205
- Neuromodulation Dspsbls and Accs$174
- PERCEPT PC BRAINSENSE$148
- Leqembi$123
- MYOBLOC$121
- APOKYN$121
- Xadago$121
- ZEPOSIA$102
How this compares
$265,148 in reported general payments places this provider in the 90th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 73 | $976,072 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $424,144 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 26 | $386,125 |
| CopaxoneGlatiramer Acetate | 54 | $320,010 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 38 | $310,648 |
| AubagioTeriflunomide | 12 | $109,678 |
| Nurtec OdtRimegepant Sulfate | 41 | $82,844 |
| FycompaPerampanel | 33 | $62,588 |
| NuplazidPimavanserin Tartrate | 13 | $53,972 |
| Glatiramer Acetate | 14 | $50,685 |
| GlatopaGlatiramer Acetate | 24 | $50,065 |
| NuedextaDextromethorphan Hbr/Quinidine | 25 | $45,442 |
| NeurontinGabapentin | 19 | $39,704 |
| TopamaxTopiramate | 15 | $29,602 |
| RytaryCarbidopa/Levodopa | 27 | $18,391 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Nurtec Odt, Dilantin | $130 | $1,063,619133 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $40 | $386,12526 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $64,852 | $320,01054 claims |
| CSL BehringPrivigen | $133 | $310,64838 claims |
| SanofiAubagio | $209 | $109,67812 claims |
| Eisai Inc.Fycompa | $440 | $62,58833 claims |
| Acadia Pharmaceuticals IncNuplazid | $165 | $53,97213 claims |
| SandozGlatopa | $18 | $50,06524 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $32 | $45,44225 claims |
| Amneal Pharmaceuticals LLCRytary | $276 | $18,39127 claims |
| UCB, Inc.Neupro | $160 | $16,40715 claims |
| AbbVieQulipta | $67,716 | $11,60211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Pottsville
- David WeismanAbington$9.3M
- Amit Bar-OrPhiladelphia$7.7M
- Thomas LeistPhiladelphia$5.8M
- Jan DrappatzPittsburgh$4M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Paula ClemensPittsburgh$2.1M
- Anoopum GuptaPittsburgh$2M
- Daniel KremensPhiladelphia$1.9M
- Frances JensenPhiladelphia$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.